UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000026750
Receipt number R000030710
Scientific Title Observation of clinical outcome of bronchial asthma with allergic rhinitis caused by house dust mite
Date of disclosure of the study information 2017/03/30
Last modified on 2020/04/03 10:40:01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Observation of clinical outcome of bronchial asthma with allergic rhinitis caused by house dust mite

Acronym

Treatment for asthma with rhinitis by dust mite

Scientific Title

Observation of clinical outcome of bronchial asthma with allergic rhinitis caused by house dust mite

Scientific Title:Acronym

Treatment for asthma with rhinitis by dust mite

Region

Japan


Condition

Condition

Bronchial asthma with allergic rhinitis caused by house dust mite

Classification by specialty

Pneumology Clinical immunology Oto-rhino-laryngology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the efficacy of treatment for allergic disease in the upper and lower airway from a clinical view and immunological biomarkers

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

Change in symptoms and medication for allergic rhinitis and asthma by treatment with medicine or sublingual immunotherapy for 3 years

Key secondary outcomes

1. Change in allergic response in nasal mucosa and skin prick test
2. Change in allergic parameters in peripheral blood
3. Compliance of sublingual immunotherapy
4. Safety (adverse event)


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit

65 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Bronchial asthma with allergic rhinitis with disease duration of more than 1 year
2. Sensitization to HDM (specific IgE by ImmunoCAP is greater than or equal to class 2)
3. Positive nasal challenge test to house dust allergen
4. Bronchial asthma as follows;
a. Mild to moderate severity, not in acute exacerbation
b. FEV1 is greater than or equal to 70% of predicted value
c. Reversible respiratory symptoms
d. Negative specific IgE (class 0 or 1) to dog, cat, Alternaria, and Aspergillus
5. Be willing to receive medication therapy or allergen immunotherapy for bronchial asthma with allergic rhinitis

Key exclusion criteria

1. Pregnant or breastfeeding female
2. Patients with sino-nasal disease that might confound accurate determination of the outcomes of the study
3. Patients with severe asthma
4. Smoker or pet keeper
5. Patients with episode of life-threatening treatment-related adverse event
6. Patients with malignant disease or severe systemic disease which affect immune system
7. Patients who cannot receive sublingual immunotherapy by other reasons

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Sawako
Middle name
Last name Masuda

Organization

National Hospital Organization Mie National Hospital

Division name

Department of Otorhinolaryngology

Zip code

514-0125

Address

357 Osato-Kubota, Tsu, Mie 514-0125, Japan

TEL

059-232-2531

Email

masudas@mie-m.hosp.go.jp


Public contact

Name of contact person

1st name Satoko
Middle name
Last name Usui

Organization

National Hospital Organization Mie National Hospital

Division name

Department of Otorhinolaryngology

Zip code

514-0125

Address

357 Osato-Kubota, Tsu, Mie 514-0125, Japan

TEL

059-232-2531

Homepage URL


Email

usuis@mie-m.hosp.go.jp


Sponsor or person

Institute

National Hospital Organization Mie National Hospital

Institute

Department

Personal name



Funding Source

Organization

Torii Pharmaceutical Co., LTD

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Review Committee of National Hospital Organization Mie National Hospital

Address

357 Osato-Kubota, Tsu, Mie 514-0125, Japan

Tel

059-232-2531

Email

suga.shigeru.ke@mail.hosp.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 03 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2016 Year 12 Month 14 Day

Date of IRB

2016 Year 05 Month 26 Day

Anticipated trial start date

2016 Year 12 Month 14 Day

Last follow-up date

2023 Year 10 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Improvement of allergic rhinitis and asthma is expected by treatment with medicine or sublingual immunotherapy. We evaluate the clinical symptoms and biomarkers in the regular medical practice for 3 years.


Management information

Registered date

2017 Year 03 Month 29 Day

Last modified on

2020 Year 04 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030710


Research Plan
Registered date File name
2019/01/10 舌下免疫臨床研究計画書(20181212).doc

Research case data specifications
Registered date File name

Research case data
Registered date File name